Compare NWBI & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWBI | NNNN |
|---|---|---|
| Founded | 1896 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | NWBI | NNNN |
|---|---|---|
| Price | $13.34 | $25.65 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 73.0K |
| Earning Date | 01-26-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | ★ 16.74 | N/A |
| EPS | ★ 0.92 | 0.06 |
| Revenue | ★ $599,086,000.00 | $6,920,153.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | ★ $14.39 | $410.25 |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $10.75 | $5.18 |
| 52 Week High | $13.62 | $55.65 |
| Indicator | NWBI | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 44.80 |
| Support Level | $13.07 | $22.10 |
| Resistance Level | $13.59 | $34.00 |
| Average True Range (ATR) | 0.30 | 6.84 |
| MACD | 0.08 | -0.40 |
| Stochastic Oscillator | 81.10 | 22.21 |
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.